Inspire Pharmaceuticals (ISPH) Announces $1.25M Milestone Payment
More News related to ISPH
- Beacon Equity Issues Technical Trade Alerts on Market Movers: CABN, ISPH, GFIG, COMS, MERC, ATML
- Inspire Initiates Special Protocol Assessment Process for Prolacria(TM) Trial for Dry Eye
- Inspire Announces Webcast of Presentation at UBS Conference
- Inspire Announces Plans for Clinical Testing of New Compound INS117548 for the Treatment of Glaucoma
- Morgan Stanley Downgrades Inspire Pharmaceuticals (ISPH) to Underweight
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the receipt of a $1.25 million milestone payment from its Asian dry eye partner, Santen Pharmaceutical Co., Ltd., related to the completion of Santen’s Phase 3 testing of diquafosol tetrasodium, referred to as DE-089, for the treatment of dry eye.
Santen has announced that it expects to file an application by the end of June 2008 for marketing approval in Japan.
Related Categories
FDAStocks Mentioned
-0.44Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
